The GLP-1 receptor agonist lixisenatide reduces postprandial glucose in patients with diabetes secondary to total pancreatectomy: a randomised, placebo-controlled, double-blinded crossover trial-Reference-Cited by-同舟云学术

The GLP-1 receptor agonist lixisenatide reduces postprandial glucose in patients with diabetes secondary to total pancreatectomy: a randomised, placebo-controlled, double-blinded crossover trial

Published:2020-05-11 Issue:7 Volume:63 Page:1285-1298
ISSN:0012-186X
Container-title:Diabetologia
language:en
Short-container-title:Diabetologia

Author:

Juel Caroline T. B.,Lund Asger,Andersen Maria M.,Hansen Carsten P.,Storkholm Jan H.,Rehfeld Jens F.,van Hall Gerrit,Hartmann Bolette,Wewer Albrechtsen Nicolai J.,Holst Jens J.,Vilsbøll Tina,Knop Filip K.^ORCID

Funder

Sanofi

Publisher

Springer Science and Business Media LLC

Subject

Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

https://link.springer.com/content/pdf/10.1007/s00125-020-05158-9.pdf

Reference36 articles.

1. Holst JJ (2004) On the physiology of GIP and GLP-1. Horm Metab Res 36(11–12):747–754. https://doi.org/10.1055/s-2004-826158

2. Hare KJ, Knop FK, Asmar M et al (2009) Preserved inhibitory potency of GLP-1 on glucagon secretion in type 2 diabetes mellitus. J Clin Endocrinol Metab 94(12):4679–4687. https://doi.org/10.1210/jc.2009-0921

3. Larsson H, Holst JJ, Ahrén B (1997) Glucagon-like peptide-1 reduces hepatic glucose production indirectly through insulin and glucagon in humans. Acta Physiol Scand 160(4):413–422. https://doi.org/10.1046/j.1365-201X.1997.00161.x